AM-2201 (1-(5-fluoropentyl)-3-(1-naphthoyl)indole) is a recreational designer drug that acts as a potent but nonselective full agonist for the cannabinoid receptor. It is part of the AM series of cannabinoids discovered by Alexandros Makriyannis at Northeastern University.

Hazards

Convulsions have been reported including at doses as low as 10mg.

Pharmacology

AM-2201 is a full agonist for cannabinoid receptors. Affinities are: with a Ki of 1.0nM at CB1 and 2.6nM at CB2. The 4-methyl functional analog MAM-2201 probably has similar affinities.[original research?] AM-2201 has an EC50 of 38nM for human CB1 receptors, and 58nM for human CB2 receptors. AM-2201 produces bradycardia and hypothermia in rats at doses of 0.3–3mg/kg, comparable to the potency of JWH-018 in rats, suggesting potent cannabinoid-like activity.

Pharmacokinetics

AM-2201 metabolism differs only slightly from that of JWH-018. AM-2201 N-dealkylation produces fluoropentane instead of pentane (or plain alkanes in general).[citation needed]

Detection

A forensic standard of AM-2201 is available, and the compound has been posted on the Forendex website of potential drugs of abuse.

Legal status

In the United States, AM-2201 is a Schedule I controlled substance.

See also